Bristol Regains Respect With New Nivolumab Filing In Melanoma
Executive Summary
While still behind Merck’s pembrolizumab, Bristol could see back-to-back approvals in lung cancer and melanoma in early 2015.
You may also be interested in...
Merck Drives Into Immunotherapy “Wild West” With New Trials
Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Bristol’s combo demonstrates similar response rate as PD-1 alone, but with much better survival rates in a small melanoma study presented at ASCO. Due to toxicities, including one death, some say combination would need to shore up survival benefit to become first choice in frontline therapy.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.